11 results about "Clusterin" patented technology

The invention relates to the technical field of inflammation detection, in particular to an auxiliary diagnosis kit for sex hormone imbalance type prostatitis. The Clusterin in the prostatic fluid can be used as an auxiliary diagnosis marker of the sex hormone imbalance type prostatitis, so that the sex hormone imbalance type prostatitis can be diagnosed by detecting the level of the Clusterin in the prostatic fluid. According to the present invention, the anti-human Clusterin antibody is prepared into the detection kit, and the detection kit can be used for auxiliary diagnosis of sex hormone imbalance type prostatitis.

The present invention relates to a method for predicting the outcome of liver transplantation for the treatment of hepatocellular carcinoma (HCC), or a method for arranging HCC patients to receive liver transplantation, comprising the following steps: determining the expression levels of indicator genes (including skin pontin, clusterin, calpain small subunit 1, F-box and WD repeat protein 7 and SproutyRTK signaling antagonist 2) selected from liver samples of patients suffering from HCC, and comparing the expression levels of the indicator genes with the expression levels of internal reference genes, and combining this with the variable total tumor volume through a linear support vector machine algorithm to predict a good prognosis for the liver transplant recipient.

The invention provides a recombinant cluster and application, the recombinant cluster comprises an amino acid primary sequence for coding the recombinant cluster, the amino acid primary sequence is at least 95% homologous with any one of SEQ ID NO.1-17, and a tertiary structure formed by the amino acid primary sequence does not have a disulfide bond. The recombinant cluster provided by the invention can greatly improve the yield of purification after escherichia coli expression, simplifies the production process, and realizes industrial large-scale production; the space structure of the recombinant cluster is free of artificially added sequences or structures, so that immunogenicity reaction is not easily induced, no other toxic or side effect exists, and the druggability is strong; in animal experiments, heat aggregation of protein can be inhibited, an obvious protection effect on oxidative stress of HCE-T cells is achieved, a new choice is provided for treatment of various animal diseases, and the good clinical application value is achieved.

The present invention relates to the technical field of inflammation detection, and in particular to an auxiliary diagnosis kit for sex hormone imbalance type prostatitis. Clusterin in prostatic fluid can be used as an auxiliary diagnosis marker for sex hormone imbalance type prostatitis, so sex hormone imbalance type prostatitis can be diagnosed by detecting the level of Clusterin in prostatic fluid. In the present invention, anti-human Clusterin antibodies are prepared into a detection kit, which can be used for auxiliary diagnosis of sex hormone imbalance type prostatitis.

The invention provides a Clusterin positive heart organoid and an application of the Clusterin positive heart organoid. The Clusterin positive heart organoid prepared by the method provided by the invention has more diverse cell compositions, and can better simulate the environment of the heart in a human body. The Clusterin positive heart organoid can be used for better improving the heart function.

Provided in the present invention are a clusterin-positive heart organoid and the use thereof. The clusterin-positive heart organoid prepared by means of the method of the present invention has more diversified cellular compositions, and can better simulate the environment of the heart in a human body. The clusterin-positive heart organoid can better improve cardiac functions.

The present invention concerns clusterin for use in the treatment of thrombotic microangiopathies, and a pharmaceutical composition comprising clusterin for use in the treatment of thrombotic microangiopathies, said composition not comprising von Willebrand factor protease. The present invention also concerns an ex vivo method for stratifying a patient suffering, or likely to be suffering, from TMA, comprising the following steps: 1) measuring, in a biological sample from said patient, the amount LC of clusterin, and 2) comparing the amount Lc measured in step 1) with an amount Lref of clusterin by calculating the score S1=LC / Lref, in which: •If S1≤1, the patient is considered to be likely to benefit from a treatment of the TMA with clusterin, •If S1>1, the patient is not considered to be likely to benefit from treatment of TMA with clusterin.

The invention provides an application of a biomarker in predicting a gastric cancer immunotherapy effect and a related product. The biomarker is clustered protein. The gastric cancer treatment effect of the anti-PD-1 antibody can be predicted by detecting the expression level of clusterin or mRNA thereof in a gastric cancer tumor cell or tumor tissue sample. Furthermore, by inhibiting the expression level of clusterin, the gastric cancer treatment effect of the anti-PD-1 antibody can be improved. A new biomarker cluster protein is provided for predicting the gastric cancer treatment effect, and the cluster protein can be used as a novel target spot of the gastric cancer, so that a new direction is provided for screening drugs for treating the gastric cancer and treating the gastric cancer.

This disclosure features clusterin (CLU) as a multifunctional biotherapeutic for promoting ocular nerve regeneration for various ocular conditions. This disclosure features methods of using CLU for treating a subject with an ocular disorder, condition, or disease (e.g., an ocular surface disease, corneal disease or retinal disease). The methods described herein can be used for the treatment of ocular inflammatory conditions involving barrier disruption and nerve loss due to its ability to protect and promote the regeneration of ocular nerves.

The invention relates to a method of determining whether an individual has Parkinson's disease, the method comprising: determining the level of markers in a bodily fluid sample from the individual, wherein the markers comprise Protein disulphide isomerase A1 (PDIA1), Protein disulphide isomerase A3 (PDIA3), Mesencephalic astrocyte-derived neurotrophic factor (MANF) and clusterin; wherein an increase in the level of PDIA1, MANF, and clusterin, and decrease in the level of PDIA3 relative to a reference level in combination with the individual's age and gender, is indicative of the individual having Parkinson's disease; and associated compositions, uses and methods.

The invention discloses a Clusterin affinity peptide and a preparation method and application of long-circulating nanoparticles modified by the Clusterin affinity peptide, and relates to the technical field of biological medicines. According to the invention, the polypeptide with high affinity and selectivity with the Human Clusterin recombinant protein is obtained through multiple rounds of library panning enrichment by a phage display technology. When the polypeptide is applied to preparation of curcumin long-circulating nanoparticles, the half-life period of the medicine can be prolonged, and the acute lung injury treatment effect can be enhanced.